CEO: Don Crawford
Starting with coronary artery disease (CAD), Analytics 4 Life is combining artificial intelligence and mathematical modeling to accelerate the accurate diagnosis of disease and connect patients to the appropriate treatments more quickly.
Analytics 4 Life is seeking de novo clearance from the FDA for its CorVista platform for the detection of CAD. Based on the company’s Phase Space Tomography technology, CorVista measures and mathematically models signals emitted by the heart to identify areas of ischemia, or where blood flow is blocked.
“This allows us to produce a diagnostic test that a physician can use to identify coronary artery disease without the need for radiation or to exercise a distressed heart,” said CEO Don Crawford.
What makes Analytics 4 Life fierce
CAD, caused by plaque buildup in the coronary arteries, is the most common form of heart disease in the U.S. Physicians look for it with a battery of tests, from stress testing—which requires the patient to exercise—and electrocardiograms to coronary angiography, which involves injecting the patient with a contrast dye.
Existing diagnostic methods are very capital-intensive, Crawford said: “The patient has to travel because only major centers can afford it.” So Analytics 4 Life is working to create a piece of equipment that can be used in any physician’s exam room, emergency room, or hospital room, he said.
A patient comes in and undergoes a noninvasive CorVista scan, which takes under three minutes. The technology scans for six different signals, collecting millions of data points.
“The heart produces energy, and the healthy heart does so in a very predictable way,” said Crawford. “Beat after beat, energy moves through the heart in a very predictable fashion that can be seen by our sensors.”
The patient’s scan is then sent to the cloud, where the company’s software analyzes it, returning a three-dimensional picture of the heart, with areas of ischemia highlighted. The physician may then use this model to guide treatment decisions.
In addition to removing the invasive, radioactive and stressful aspects of CAD diagnostics, the tech could also cut the time it takes to produce a diagnosis, getting patients the correct treatment more quickly.
What to look for
In September, the company bagged $25 million in its series B round, to bring its CorVista system through the final stage of clinical testing. It reported early data from its learning database at the Transcatheter Cardiovascular Therapeutics conference.
Analytics 4 Life expects to complete enrollment for its 3,000-patient clinical trial by the end of the year. It will use the results from this trial to apply for de novo clearance from the FDA in the first half of 2018. Pending approval, the company plans to roll the device out in the second half of next year.